Accelerate Diagnostics, Inc. (NASDAQ: AXDX), announced preliminary financial results for the quarter ending December 31, 2018. The company reported a 127.2% increase in U.S.instruments placed under commercial contract during the fourth quarter, and full-year revenue of $5.7 million, an increase of 35.7% from the prior year (see also Accelerate Diagnostics Inc.).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.